The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is chemo-free ponatinib, venetoclax, and dexamethasone safe/effective in patients with R/R Ph+ ALL?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Nicholas J. Short, MD Anderson Cancer Center, Houston, US. We asked, Is chemo-free ponatinib, venetoclax, and dexamethasone safe/effective in patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) ALL?

Is chemo-free ponatinib, venetoclax, and dexamethasone safe/effective in patients with R/R Ph+ ALL?

In this video, Short discusses data from phase I of a phase I/II study on the combination of ponatinib, venetoclax, and dexamethasone in patients with relapsed/refractory Ph+ ALL, where outcomes are traditionally very poor.


Share: